LEDIPASVIR; SOFOSBUVIR - Generic Drug Details

What are the generic sources for ledipasvir; sofosbuvir and what is the scope of patent protection?

Ledipasvir; sofosbuvir is the generic ingredient in one branded drug marketed by Gilead Sciences Inc and is included in two NDAs. There are seventeen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ledipasvir; sofosbuvir has five hundred and sixty-five patent family members in fifty countries.

Two suppliers are listed for this compound.

Summary for LEDIPASVIR; SOFOSBUVIR

International Patents:	565
US Patents:	17
Tradenames:	1
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Clinical Trials:	98
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LEDIPASVIR; SOFOSBUVIR
DailyMed Link:	LEDIPASVIR; SOFOSBUVIR at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LEDIPASVIR; SOFOSBUVIR

Constraining patent/regulatory exclusivity:

8,088,368*PED

Dosage:

PELLETS;ORAL

Constraining patent/regulatory exclusivity:

8,088,368*PED

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LEDIPASVIR; SOFOSBUVIR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mansoura University	Phase 3
Helwan University	Phase 4
Cairo University	Phase 2/Phase 3

See all LEDIPASVIR; SOFOSBUVIR clinical trials

Pharmacology for LEDIPASVIR; SOFOSBUVIR

Drug Class	Hepatitis C Virus NS5A Inhibitor Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors P-Glycoprotein Inhibitors RNA Replicase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for LEDIPASVIR; SOFOSBUVIR

J05AP	Antivirals for treatment of HCV infections
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for LEDIPASVIR; SOFOSBUVIR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	TABLET;ORAL	205834-002	Aug 28, 2019		RX	Yes	No	8,633,309*PED				Y
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	PELLETS;ORAL	212477-002	Aug 28, 2019		RX	Yes	Yes	8,889,159*PED				Y
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	TABLET;ORAL	205834-002	Aug 28, 2019		RX	Yes	No	8,088,368*PED				Y
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	PELLETS;ORAL	212477-001	Aug 28, 2019		RX	Yes	No	8,273,341*PED				Y
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	TABLET;ORAL	205834-001	Oct 10, 2014		RX	Yes	Yes	8,088,368*PED				Y
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	PELLETS;ORAL	212477-002	Aug 28, 2019		RX	Yes	Yes

International Patents for LEDIPASVIR; SOFOSBUVIR

Country	Patent Number	Title	Estimated Expiration
Denmark	3002281
Serbia	56975
Mexico	351816
Peru	20150202	COMPUESTOS ANTIVIRALES
Lithuania	PA2016002
Hungary	E047777

Supplementary Protection Certificates for LEDIPASVIR; SOFOSBUVIR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2203462	201440043	Slovenia		PRODUCT NAME: SOFOSBUVIR; NATIONAL AUTHORISATION NUMBER: EU/1/13/894/001-002; DATE OF NATIONAL AUTHORISATION: 20140116; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2203462	132014902310732	Italy		PRODUCT NAME: SOFOSBUVIR(SOVALDI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/894, 20140117
2203462	1491066-5	Sweden		PRODUCT NAME: SOFOSBUVIR; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/13/894, 2014-01-17
2203462	C300704	Netherlands		PRODUCT NAME: SOVALDI (SOFOSBUVIR); REGISTRATION NO/DATE: EU/1/13/894/001-002 20140117
2430014	631	Finland
2430014	SPC/GB16/008	United Kingdom		PRODUCT NAME: LEDIPASVIR; REGISTERED: UK EU/1/14/958(001-002) 20141118

Ledipasvir/Sofosbuvir (Harvoni): Market Dynamics and Financial Trajectory

Last updated: April 25, 2026

Ledipasvir/sofosbuvir (L/S) is a direct-acting antiviral (DAA) combination for hepatitis C virus (HCV) infection. After launch, revenue scaled quickly with broad label coverage and high sustained virologic response (SVR) rates, then flattened as (1) generic competition expanded and (2) newer, pangenotypic regimens and shorter/streamlined pathways shifted prescribing. The financial trajectory is dominated by the timing and geography of patent expiry, launch of authorized generics, and the pace of uptake of subsequent DAAs.

What drove adoption and pricing power for ledipasvir/sofosbuvir?

Indication breadth and treatment simplification

L/S entered as a once-daily oral regimen across major HCV treatment settings, which reduced clinical friction compared with interferon-based regimens and many earlier DAAs. Clinical practice and payer dynamics favored regimens that minimized genotype testing complexity and simplified monitoring.

Efficacy and regimen credibility

L/S gained rapid market share because it delivered high cure rates across multiple genotypes and patient subgroups (treatment-naïve and treatment-experienced; compensated cirrhosis in many pathways). High SVR reduced retreatment risk and created strong payer confidence in total-cost-of-care framing.

Competitive set and how it changed

The competitive landscape shifted in phases:

• Early phase (launch years): L/S faced limited well-entrenched DAAs and benefited from being a benchmark combination.
• Middle phase: Competitors introduced once-daily regimens with different backbone profiles and evolving label expansions.
• Later phase: Pangenotypic options and regimens with shorter treatment durations and broader usability increasingly captured incremental demand, especially in systems that rationalized formularies.

Pricing behavior: list price vs net price reality

L/S list pricing remained high through the covered exclusivity window, but realized revenue depended on net pricing, rebates, and payer contracting. The financial pattern reflects classic specialty pharmaceutical dynamics: early high net revenue followed by pressure as competition increased and as biosimilar-style price compression did not apply but generic small-molecule compression did.

How did market dynamics evolve from peak to maturity?

Peak demand drivers

Peak revenue years tracked three vectors:

1. Scale-up of DAA adoption driven by guideline updates and reductions in therapeutic uncertainty.
2. Broad label usage across genotype groups and key clinical populations.
3. Institutional learning curves in hepatology and managed care systems.

Demand maturation

After initial expansion, the addressable pool narrowed due to:

• Lower remaining prevalence among treated populations in higher-income markets.
• More stringent access criteria over time in some systems, followed by eventual broadening as competition intensified and budgets tightened.
• Increased migration to newer regimens with easier prescribing and pan-genotypic coverage.

Generic entry and authorized generics

Market dynamics turned on generic small-molecule entry:

• Sofosbuvir and ledipasvir components became targets for generic manufacturers as exclusivity periods ended.
• Authorized generics reduced price volatility and accelerated unit volume while compressing revenue per treated patient.

Country and payer heterogeneity

The shift from branded dominance to multi-source competition occurred unevenly:

• High-income markets moved earlier and faster to generic or authorized generic substitution.
• Emerging markets followed later but at lower unit margins, driven by procurement mechanisms and local regulatory pathways.

What is the financial trajectory for ledipasvir/sofosbuvir?

Gilead revenue concentration and lifecycle

L/S was a cornerstone product for Gilead Sciences. Its financial trajectory can be inferred from Gilead’s reported revenue and segment reporting trends, where HCV regimens accounted for major branded revenue during the peak years and later declined as cure-treated cohorts grew and competition expanded.

Key lifecycle pattern:

• Rapid ramp post-launch
• Sustained growth during broad uptake
• Plateau and then decline as generic competition and newer DAAs gained share

Core drivers of revenue decline

1. Patent expiry and generic substitution reduced net price.
2. Formulary switching toward pangenotypic regimens in systems that standardized DAAs.
3. Reduced incremental patient pool in markets where HCV treatment penetration reached high levels among diagnosed populations.

Financial summary table (directional trajectory)

The table below frames the trajectory by phase and the dominant commercial mechanism.

Phase	Market mechanism	Net price trend	Volume trend	Overall revenue trend
Launch to ramp	Strong uptake; limited direct competition	High	Up	Up sharply
Growth to plateau	Broad label; payer contracting stabilizes	High to stable	Up to steady	Up then flat
Maturity	Competition increases; formulary pressure	Down	Steady to down	Flatten
Post-generic	Multiplicity of suppliers	Low	Mixed; substitution shifts mix	Down materially

How does the product’s patent and exclusivity structure map to commercial outcomes?

Exclusivity as the revenue backbone

DAA pricing power is typically sustained through composition-of-matter protection on key molecules and combinations, plus regulatory exclusivities in major jurisdictions. For L/S, long exclusivity windows on ledipasvir and sofosbuvir plus combination protection supported branded revenue until the competitive transition.

Timing of generic pressure

The financial inflection aligns with:

• End of protection for key claims
• Start of generic/authorized generic supply
• Subsequent payer substitution at scale

This is consistent with how Gilead’s HCV franchise moved from branded dominance to competitive erosion across multiple markets.

What do real-world financial signals indicate for ledipasvir/sofosbuvir?

Evidence from Gilead reporting

Gilead’s annual reporting shows HCV product revenue dominance during the peak years and later declines as the HCV franchise matured and competition intensified, with transition toward other therapeutic areas over time. The magnitude and timing of decline in Gilead’s HCV-related line items is consistent with:

• generic substitution
• reduced treated incidence among remaining untreated cohorts
• competitive share shift toward newer regimens

Where does ledipasvir/sofosbuvir still compete effectively?

Even after broader substitution, L/S can retain clinical and commercial relevance in specific conditions:

• Systems with established clinical pathways and negotiated pricing
• Patients where prescriber familiarity, lab workflows, or formulary constraints favor continuity
• Situations where alternative regimens present access friction

In practice, these pockets narrow as pangenotypic regimens become default and as procurement systems standardize.

Market structure implications for investors and strategists

What matters most for future DAAs and successors

The L/S lifecycle illustrates repeatable market mechanics:

• High initial pricing power when a regimen is both guideline-aligned and competitively differentiated
• Rapid erosion once small-molecule generic entry expands
• Share shift once formularies move toward simpler pangenotypic standards
• Accounting impacts driven by net price and mix, not just unit counts

Competitive intelligence to operationalize

For business teams evaluating DAA-like launches or late-stage pipeline assets:

• Prioritize mapping of composition and combination claim scope to country-by-country expiry.
• Tie commercial models to authorized generic likelihood and expected payer uptake timing.
• Stress-test net price curves for switching from branded to multi-source and for formulary migration to newer regimens.

Key Takeaways

• Ledipasvir/sofosbuvir is a classic high-revenue DAA whose market dynamics moved from rapid uptake to maturity and then compression as generic competition and newer regimens shifted prescribing.
• The financial trajectory is best understood through lifecycle phases: ramp, plateau, maturity, and post-generic revenue decline driven by net price compression and share loss.
• Exclusivity timing and authorized generic behavior are the dominant levers in commercial outcomes for HCV DAAs.
• The product still competes in limited pockets where payer pricing, prescriber familiarity, and formulary constraints preserve continuity, but those pockets narrow as standard-of-care consolidates around pangenotypic options.

FAQs

1) Is ledipasvir/sofosbuvir still a first-line HCV treatment in major formularies?

In many major markets, first-line use has shifted toward pangenotypic regimens, but L/S can persist in formularies under specific contracting terms or clinical workflow continuity.

2) What causes the sharp revenue drop after peak for HCV DAAs like L/S?

The dominant causes are generic and authorized generic substitution plus formulary switching as newer regimens standardize treatment pathways.

3) Does unit volume always offset branded-to-generic price declines?

Not fully. Even when treated volumes remain steady, net pricing erosion typically outweighs any volume gains in revenue models.

4) Which factor most strongly affects realized revenue: list price or net price?

Net price, determined by rebates and contracting, is the primary driver of realized revenue because competitive pressure and payer leverage change quickly as multi-source supply expands.

5) How should patent analysis be used in commercial forecasting for DAAs?

Use claim and exclusivity mapping to predict the start of generic substitution, then link that to payer switch timing and authorized generic scenarios to model net price and revenue curves.

---

References

[1] Gilead Sciences. Form 10-K Annual Reports (revenue disclosures and segment/product information for HCV franchise). U.S. Securities and Exchange Commission filings.
[2] U.S. Food and Drug Administration. Drug Approval Reports and Labeling for ledipasvir/sofosbuvir (Harvoni). FDA.
[3] European Medicines Agency. Assessment Reports and Product Information for Harvoni (ledipasvir/sofosbuvir). EMA.
[4] World Health Organization. Global hepatitis report and HCV treatment burden statistics (context for diagnosed and treated populations). WHO.